摘要
目的分析依达拉奉联合纳洛酮治疗颅脑损伤对凝血功能异常的预后价值。方法选取台州市肿瘤医院2014年2月~2017年6月收治的80例颅脑损伤患者,随机分为对照组(n=40)和实验组(n=40)。对照组进行常规治疗,保持呼吸道通畅,给予抗生素及止血和营养神经治疗,维持机体酸碱平衡,实验组患者在此基础上给予依达拉奉联合纳洛酮治疗,4mg纳洛酮+0.9%250mL氯化钠溶液,静脉滴注,同时给予30mg依达拉奉。比较分析实验组与对照组凝血酶原时间、凝血酶时间、血小板计数以及活化部分凝血酶时间。结果经过对应的治疗后,实验组患者凝血酶原时间为(16.82±2.54)s,对照组患者的凝血酶原时间为(20.72±2.33)s,2组比较差异具有统计学意义(P<0.05)。实验组患者血小板计数、活化部分凝血酶时间以及凝血酶时间指标显著优于对照组(P<0.05)。治疗后,实验组GCS评分为(9.44±1.32)分,显著高于对照组评分(8.22±1.65)分,(P<0.05)。结论依达拉奉联合纳洛酮治疗颅脑损伤能够显著改善患者的凝血功能异常,帮助患者恢复意识,具有重要预后价值。
Objective To analyze the prognostic value of edaravone combined with naloxone in the treatment of traumatic brain injury with coagulation dysfunction.Methods80cases of craniocerebral injury patients from February2014to June2017were divided into control group(n=40)and experimental group(n=40).The control group was given routine treatment,maintain airway patency,antibiotic and hemostatic and neurotrophic treatment,maintain body acid-base balance,patients in the experimental group on the basis of edaravone combined with naloxone,naloxone+Sodium Chloride Solution0.9%250mL4mg,intravenous drip,while giving30mg edaravone.The clinical indexes such as prothrombin time,thrombin time,platelet count and activated partial thromboplastin time were compared and analyzed.Results After the treatment,the patients in the experimental group for prothrombin time was(16.82±2.54)s,the prothrombin time for patients in the control group(20.72±2.33)s(P<0.05).The platelet count,activated partial thromboplastin time and thrombin time index in the experimental group were significantly better than those in the control group(P<0.05).After treatment,the score of GCS in the experimental group was(9.44±1.32)points,significantly higher than(8.22±1.65)points of the control group(P<0.05).Conclusion Edaravone combined with naloxone in the treatment of craniocerebral injury can significantly improve the abnormal coagulation function of patients,and help patients recover consciousness,which has important prognostic value.
作者
黄立朋
沈景
HUANG li-peng;SHEN Jing(Department of Acute and Critical Medical Sciences, Taizhou Cancer Hospital, Taizhou 317502, China)
出处
《中国生化药物杂志》
CAS
2017年第12期46-47,共2页
Chinese Journal of Biochemical Pharmaceutics
关键词
依达拉奉
纳洛酮
颅脑损伤
凝血功能异常
edaravone
naloxone
traumatic brain injury
coagulation dysfunction